Neutrophil-to-Lymphocyte Ratio Predicts Outcomes in mRCC and mNSCLC Patients Treated With Nivolumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Variation in Neutrophil to Lymphocyte Ratio (NLR) as Predictor of Outcomes in Metastatic Renal Cell Carcinoma (mRCC) and Non-Small Cell Lung Cancer (mNSCLC) Patients Treated With Nivolumab
Cancer Immunol. Immunother. 2020 Jun 19;[EPub Ahead of Print], A Simonaggio, R Elaidi, L Fournier, E Fabre, V Ferrari, D Borchiellini, J Thouvenin, P Barthelemy, C Thibault, E Tartour, S Oudard, YA VanoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.